Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
 |
Results for 'Nitric Oxide' |
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
|
Nitric Oxide Therapeutics, Markets and Companies |
March 2010 | £1850 | 100 % |
|
Nitromed, Inc Premium Company Profile |
December 2007 | £175 | 38.5 % |
|
Free Radicals in Ophthalmic Disorders |
March 2008 | £256 | 35 % |
|
Pain Therapeutics Drugs, Markets and Companies |
March 2010 | £2310 | 17.5 % |
|
Anti-hypertension - Drug Pipeline Analysis and Market Forecasts to 2016 |
February 2010 | £1320 | 16.5 % |
|
Pulmonary Arterial Hypertension (PAH) Drug Pipeline Analysis and Market Forecasts to 2016 |
February 2010 | £1320 | 16.5 % |
|
Human Embryo Evaluation and Selection |
August 2007 | £145 | 11.55 % |
|
Textbook of Interventional Cardiovascular Pharmacology |
April 2007 | £140 | 7.7 % |
|
Stakeholder Opinions: Cystic Fibrosis - A pipeline full of hope Healthcare |
March 2009 | £1320 | 7 % |
|
Pipeline Insight: Heart failure Week pipeline dominated by new indications and add-on diuretics |
August 2007 | £3965 | 5.95 % |
|
Cardiovascular Drug Delivery Technologies, Markets and Companies |
March 2010 | £1650 | 4.55 % |
|
Pipeline Insight: Migraine Innovation essential as weak late-stage pipeline fails to hold off the impact of triptan patent expiries |
December 2006 | £3965 | 4.55 % |
|
Alzheimer Disease New Drugs, Markets and Companies |
May 2009 | £1850 | 4.55 % |
|
Alzheimer's disease New Drugs, Markets and Companies |
October 2009 | £1980 | 4.55 % |
|
Alzheimer's disease New drugs, markets and companies |
December 2008 | £1980 | 4.55 % |
|
Alzheimer's Disease New Drugs, Markets and Companies |
February 2010 | £2115 | 4.55 % |
|
Alzheimer's Disease New Drugs, Markets and Companies |
October 2009 | £1980 | 4.55 % |
|
Immunomodulators Therapeutic Needs, Pipelines & Prospects |
August 2007 | £1495 | 4.2 % |
|
Alzheimer's disease |
March 2010 | £2115 | 4.2 % |
|
Medical Device Coatings |
November 2008 | £3205 | 3.85 % |
|
Neuroprotection Drugs, Markets and Companies |
March 2010 | £2970 | 3.5 % |
|
Transdermal Drug Delivery Technologies, Markets and Companies |
March 2010 | £1850 | 3.5 % |
|
Stakeholder Insight Asthma - over-Prescribing Is Common in Intermittent and Mild Forms of Asthma |
July 2008 | £5020 | 2.8 % |
|
Gene Therapy Technologies, Markets and Companies |
March 2010 | £2970 | 2.45 % |
|
Drug Delivery to CNS |
March 2010 | £1850 | 2.1 % |
|
Drug Delivery to Central Nervous System Diseases Technologies, Markets and Companies |
February 2010 | £1850 | 2.1 % |
|
Drug Delivery in Central Nervous System Diseases Technologies,Markets and Companies |
October 2009 | £1650 | 2.1 % |
|
Drug Delivery in Cancer Technologies, Markets and Companies |
March 2010 | £2310 | 2.1 % |
|
Cell Therapy Technologies, Markets and Companies |
March 2010 | £3300 | 2.1 % |
|
Antiviral Therapeutics Technologies, Markets and Companies |
March 2010 | £2115 | 2.1 % |
|
Biomarkers Technologies, Markets and Companies |
March 2010 | £2970 | 2.1 % |
|
Proteomics Technologies, Markets and Companies |
March 2010 | £2970 | 1.75 % |
